In 2009, researchers at Shanghai’s Ruijin Hospital reported that five-year overall survival was 91.7% in a study of 85 patients with acute promyelocytic leukemia (APL), using all-trans retinoic acid plus arsenic trioxide (Hu et al., PNAS). This historical result concerns a specific leukemia and treatment regimen, not cancer outcomes in general.
It also points to the real question behind any "best hospital" search. The best cancer hospital in Shanghai is the one that is strongest for your specific cancer. Shanghai has several nationally ranked centers, but they are not interchangeable.
The short answer: for most solid tumors, start with Fudan University Shanghai Cancer Center. For leukemia, lymphoma and myeloma, look at Ruijin Hospital. For liver cancer, Zhongshan Hospital, Fudan University is the reference center. Below, we explain why, what the evidence actually shows, and what to check before you book a flight.
Key Takeaways |
|
Table of Contents
How We Chose These Three Hospitals
This is a practical shortlist, not a formal ranking. Each hospital was chosen for relevant specialist expertise and published clinical research: FUSCC for solid tumors, Ruijin for blood cancers and Zhongshan for liver cancer. The appropriate department and international-patient intake pathway still require confirmation.
That said, "top" does not mean "right for everyone." A lung cancer patient, for example, may be better served at Shanghai Chest Hospital. Your diagnosis should drive the choice.
Fudan University Shanghai Cancer Center (FUSCC): Breadth for Solid Tumors
Founded in 1931, FUSCC is a dedicated cancer hospital affiliated with Fudan University. Its official hospital overview reports 2,177 beds at the end of 2025 and more than 2.5 million outpatient visits during 2025 across its campuses. The relevant subspecialty team matters more than hospital size alone.
Where it stands out: precision treatment for breast cancer. FUSCC researchers developed a way to split triple-negative breast cancer — a hard-to-treat subtype — into molecular subgroups, then matched each subgroup to a targeted drug or immunotherapy. In the FUTURE phase II trial (141 patients who had already received a median of three prior treatments for metastatic disease), 29.8% saw their tumors shrink significantly. Median progression-free survival was 3.4 months and median overall survival was 10.7 months, with no treatment-related deaths (Cell Research, 2023).
What this means for you: these are meaningful numbers for patients who had run out of standard options, but a 29.8% response rate is not a cure rate. FUTURE was a research study, so its specific drug combinations may not be offered as routine care. Subtyping-based treatment decisions, however, are part of how FUSCC approaches breast cancer today.
Ruijin Hospital: A Leader in Blood Cancers and CAR-T
Ruijin Hospital, affiliated with Shanghai Jiao Tong University, hosts the Shanghai Institute of Hematology. In its 2009 APL study, 94.1% of 85 patients achieved complete remission; median follow-up was 70 months. These results cannot be generalized to other leukemias or individual patients.
Where it stands out today: blood-cancer and cellular-therapy research. Ruijin’s hematology faculty describe work on CAR-T, TCR-T and multiple myeloma. Separately, China approved ciltacabtagene autoleucel in 2024 for adults with relapsed or refractory multiple myeloma after at least three prior lines including a proteasome inhibitor and an immunomodulatory drug (manufacturer regulatory disclosure). Approval does not confirm current access at Ruijin or eligibility for an international patient.
What this means for you: Ruijin can be a strong option for leukemia, lymphoma and myeloma, including patients who have relapsed. Whether you can receive an approved CAR-T product or join a newer trial depends on your diagnosis, prior treatments and the trial's entry rules. Not every trial accepts international patients.
Zhongshan Hospital, Fudan University: Liver Cancer Expertise
Zhongshan Hospital, Fudan University, has a major liver-cancer program spanning surgery, transplantation and multidisciplinary treatment. Its specialists have led clinical research on when surgery may become appropriate after systemic therapy.
Where it stands out: reassessing surgery after systemic treatment. The 24-center TALENTOP trial (Lancet, 2026; NCT04649489) enrolled 489 people with hepatocellular carcinoma invading major blood vessels, without extrahepatic spread. After induction therapy, 201 selected patients with response or stable disease and feasible resection were randomized. Median time to treatment failure was 20.4 months with surgery versus 11.8 months with continued systemic therapy. Overall-survival data were immature. Grade 3–4 treatment-related adverse events occurred in 39% versus 21% of the safety populations; two treatment-related deaths occurred in the surgery group.
What this means for you: if you were told your liver cancer is inoperable, a second surgical opinion at a high-volume center may be worth seeking. It is not a promise that surgery will become possible.
Hospitals and Specialists to Consider
Fudan University Shanghai Cancer Center
Ruijin Hospital
Zhongshan Hospital, Fudan University
Images: hospital, Shanghai municipal government and university sources. Doctor profiles identify relevant expertise; appointments and international-patient access must be confirmed.
Which Shanghai Hospital Fits Your Cancer?
Ask for an individualized written cost estimate. Charges vary by cancer type, investigations, drugs, procedures and length of stay. Check exclusions such as accommodation, interpretation, medicines, follow-up and treatment of complications before comparing total costs.
What International Patients Should Know Before Seeking Treatment in Shanghai
Your records need to travel well. Gather the pathology report, recent CT, MRI or PET imaging, biomarker results and a dated treatment summary. Ask which documents require Chinese or English translation and whether the hospital needs original pathology slides or blocks for re-review.
Trials and standard care are different things. Many headlines about Chinese hospitals describe clinical trials. A trial may close, may only enroll Chinese residents, or may require specific prior treatments. Confirm the status of any therapy before you plan travel.
Continuity of care matters. Treatment such as CAR-T requires weeks of monitoring nearby, and you will need a doctor at home who can manage follow-up. Plan both ends before you start.
Getting Independent Guidance Before You Travel
ChinaCureLink (chinacurelink.com), a Medebound HEALTH company, is an independent medical facilitator and patient advocate helping international patients explore serious disease treatment in the US or in China. Founded by physicians 10 years ago, it has helped around 3,000 international patients.
In practice, this means someone reviews your diagnosis, pathology, biomarkers and past treatment before you choose a hospital. ChinaCureLink represents the patient, not any single hospital, and can match your case with up to three relevant Chinese hospitals. It can also help arrange a video second opinion with a Chinese specialist before you decide whether to travel. Our hospital and specialist matching service is free. Video second opinions are separate paid specialist consultations, with fees confirmed before booking. On-site coordination services are charged separately if you travel.
Patient Case Studies
These previously published Shanghai CAR-T stories describe individual experiences, not results at all three hospitals or a prediction of your outcome. Long-term follow-up and specialist assessment remain essential.
Patient Experiences
These testimonials describe patient coordination and second-opinion services. They do not measure cancer-treatment outcomes or endorse the hospitals listed above.
Your Next Steps
Frequently Asked Questions
Which is the best cancer hospital in Shanghai? There is no single best hospital for every cancer. Fudan University Shanghai Cancer Center is the city's dedicated cancer hospital and a strong default for solid tumors. Ruijin Hospital is a leading choice for blood cancers, and Zhongshan Hospital for liver cancer.
Do Shanghai cancer hospitals accept foreign patients? International medical services are available in Shanghai, including at Ruijin and Zhongshan. Contact the chosen hospital to confirm acceptance for your diagnosis, language support, appointments and the relevant treatment. A clinical trial may apply different enrollment rules.
Is CAR-T therapy available to foreigners in Shanghai? Some approved CAR-T products are used in Shanghai hospitals for specific blood cancers. Investigational CAR-T trials may or may not accept international patients. Eligibility depends on diagnosis, prior lines of treatment and overall health.
The Bottom Line
Shanghai offers research-active cancer care, with different strengths at each center. FUSCC brings depth in solid tumors, Ruijin in blood cancers and Zhongshan in liver-cancer care. Many promising results come from trials and apply only to selected patients.
The safest next step is to have your records reviewed by a specialist before you make travel plans. That one step can tell you whether Shanghai has something meaningfully different to offer for your situation.
About ChinaCureLink
ChinaCureLink is an independent medical facilitator and patient advocate. We help international patients organize records, compare relevant hospitals and obtain specialist opinions before making travel decisions.
Medical Disclaimer
This guide is for general information and does not replace diagnosis or advice from your treating clinician. Hospital selection, treatment access and trial eligibility require individual assessment. Research results and patient stories do not guarantee outcomes. Confirm current clinical services, risks, fees and follow-up arrangements directly with the hospital before travel.
